HRP20031027A2 - Pediatric formulation of gatifloxacin - Google Patents

Pediatric formulation of gatifloxacin Download PDF

Info

Publication number
HRP20031027A2
HRP20031027A2 HR20031027A HRP20031027A HRP20031027A2 HR P20031027 A2 HRP20031027 A2 HR P20031027A2 HR 20031027 A HR20031027 A HR 20031027A HR P20031027 A HRP20031027 A HR P20031027A HR P20031027 A2 HRP20031027 A2 HR P20031027A2
Authority
HR
Croatia
Prior art keywords
gatifloxacin
fatty acid
acid
crystalline
coprecipitate
Prior art date
Application number
HR20031027A
Other languages
English (en)
Croatian (hr)
Inventor
S. Raghavan Krishnaswamy
A. Ranadive Sunanda
S. Bembenek Kenneth
Benkerrour Loutfy
Trognon Veronique
G. Corrao Richard
Esposito Luigi
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20031027A2 publication Critical patent/HRP20031027A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
HR20031027A 2001-06-20 2002-05-10 Pediatric formulation of gatifloxacin HRP20031027A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29962501P 2001-06-20 2001-06-20
PCT/US2002/014596 WO2003000175A2 (en) 2001-06-20 2002-05-10 Pediatric formulation of gatifloxacin

Publications (1)

Publication Number Publication Date
HRP20031027A2 true HRP20031027A2 (en) 2005-10-31

Family

ID=23155586

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20031027A HRP20031027A2 (en) 2001-06-20 2002-05-10 Pediatric formulation of gatifloxacin

Country Status (29)

Country Link
US (1) US6589955B2 (pl)
EP (1) EP1406572A4 (pl)
JP (1) JP4617475B2 (pl)
KR (1) KR100888519B1 (pl)
CN (1) CN1264514C (pl)
AR (1) AR034483A1 (pl)
AU (1) AU2002345534B2 (pl)
BG (1) BG108444A (pl)
BR (1) BR0209692A (pl)
CA (1) CA2450742A1 (pl)
CZ (1) CZ20033487A3 (pl)
EE (1) EE200400018A (pl)
GE (1) GEP20053610B (pl)
HR (1) HRP20031027A2 (pl)
HU (1) HUP0401497A2 (pl)
IL (1) IL158863A0 (pl)
IS (1) IS7048A (pl)
MX (1) MXPA03011451A (pl)
NO (1) NO20035605D0 (pl)
NZ (1) NZ529611A (pl)
PE (1) PE20030126A1 (pl)
PL (1) PL366559A1 (pl)
RU (1) RU2288218C2 (pl)
SK (1) SK14152003A3 (pl)
TW (1) TWI224004B (pl)
UA (1) UA75656C2 (pl)
WO (1) WO2003000175A2 (pl)
YU (1) YU100303A (pl)
ZA (1) ZA200309173B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258349B1 (en) 2004-05-11 2014-07-16 Egalet Ltd. Swellable dosage form comprising gellan gum
US8524735B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070051418A1 (en) * 2005-09-02 2007-03-08 Rowles Brian A Multilayer tubes
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
CA2739897C (en) * 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
CA2739893C (en) 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
SI2473170T1 (sl) 2009-09-04 2019-10-30 Horizon Orphan Llc Uporaba aerosoliziranega levofloksacina za zdravljenje cistične fibroze
CN102397552B (zh) * 2010-09-10 2016-06-08 广州自远生物科技有限公司 一种含喹诺酮类的药物复合制剂及其制备方法和应用
CN102397546A (zh) * 2010-09-10 2012-04-04 广州自远生物科技有限公司 一种用于嗅觉或味觉敏感型动物的药物给药方法
EP2969004B1 (en) 2013-03-15 2026-02-25 Melinta Subsidiary Corp. Delafloxacin for use in treating infections in obese patients
WO2018129079A1 (en) * 2017-01-03 2018-07-12 Thermolife International, Llc Method of isolating theacrine and composition comprising theacrine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO88836A2 (ro) 1983-10-11 1986-03-31 Institutul Pentru Controlul De Stat Al Medicamentului Si Cercetari Farmaceutice,Ro Procedeu de obtinere a comprimatelor cu eritromicina propionat de uz pediatric
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US5405617A (en) 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
IT1255792B (it) 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US5407921A (en) 1993-07-01 1995-04-18 Kao Corporation Method for suppressing bitter taste
JP3449658B2 (ja) 1994-12-21 2003-09-22 杏林製薬株式会社 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法
DE19633480A1 (de) 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
CA2227314A1 (en) 1997-01-24 1998-07-24 Hoechst Aktiengesellschaft Preparation of concealed taste preparations of antibacterially active quinolone derivatives
GB9702799D0 (en) 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
PT1200129E (pt) 1999-07-14 2008-12-17 Schering Plough Ltd Máscara de sabor para preparações orais líquidas de quinolona com utilização de resinas de permuta iónica

Also Published As

Publication number Publication date
EP1406572A2 (en) 2004-04-14
HUP0401497A2 (hu) 2004-12-28
KR20040011543A (ko) 2004-02-05
BR0209692A (pt) 2004-04-20
AU2002345534B2 (en) 2007-07-12
NZ529611A (en) 2006-02-24
CA2450742A1 (en) 2003-01-03
YU100303A (sh) 2006-08-17
AR034483A1 (es) 2004-02-25
EE200400018A (et) 2004-04-15
US6589955B2 (en) 2003-07-08
BG108444A (en) 2004-08-31
CZ20033487A3 (cs) 2004-05-12
US20030028025A1 (en) 2003-02-06
WO2003000175A2 (en) 2003-01-03
CN1264514C (zh) 2006-07-19
RU2288218C2 (ru) 2006-11-27
JP2005500306A (ja) 2005-01-06
TWI224004B (en) 2004-11-21
UA75656C2 (en) 2006-05-15
IL158863A0 (en) 2004-05-12
KR100888519B1 (ko) 2009-03-11
CN1518449A (zh) 2004-08-04
GEP20053610B (en) 2005-09-12
JP4617475B2 (ja) 2011-01-26
RU2003136068A (ru) 2005-02-10
PL366559A1 (pl) 2005-02-07
SK14152003A3 (sk) 2004-06-08
MXPA03011451A (es) 2004-04-05
IS7048A (is) 2003-11-20
ZA200309173B (en) 2005-02-25
WO2003000175A3 (en) 2003-04-10
EP1406572A4 (en) 2005-05-25
PE20030126A1 (es) 2003-02-08
NO20035605D0 (no) 2003-12-16

Similar Documents

Publication Publication Date Title
RU2126257C1 (ru) Фармацевтическая композиция со сниженным горьким вкусом, содержащая азалид, и способ лечения бактериальной инфекции у млекопитающих (варианты)
CA2166891C (en) Method for making freeze dried drug dosage forms
CA2377916C (en) Taste masked pharmaceutical liquid formulations
AU2008320458A1 (en) Stabilized pediatric suspension of carisbamate
HRP20031027A2 (en) Pediatric formulation of gatifloxacin
US9918941B2 (en) Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them
AU2002345534A1 (en) Pediatric formulation of gatifloxacin
AU2010351281B2 (en) Ciprofloxacin dry syrup composition
CZ20014133A3 (cs) Farmaceutický přípravek a způsob jeho přípravy
DE10149652A1 (de) Mittel zur peroralen Verabreichung von Natriumbenzoat, seine Herstellung und Verwendung

Legal Events

Date Code Title Description
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20070412

Year of fee payment: 6

OBST Application withdrawn